Cargando…

Perioperative changes in serum CA125 levels: a prognostic factor for disease-specific survival in patients with ovarian cancer

OBJECTIVE: In patients with advanced stage epithelial ovarian cancer (EOC) the volume of residual tumor after debulking is known as prognostic factor for survival. We wanted to examine the relationship between postoperative decline in serum CA125 and residual disease after cytoreductive surgery and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zwakman, Nienke, van de Laar, Rafli, Van Gorp, Toon, Zusterzeel, Petra LM, Snijders, Marc PML, Ferreira, Isabel, Massuger, Leon FAG, Kruitwagen, Roy FPM
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5165075/ https://www.ncbi.nlm.nih.gov/pubmed/27670261 http://dx.doi.org/10.3802/jgo.2017.28.e7

Ejemplares similares

Cytoreductive surgery followed by chemotherapy versus chemotherapy alone for recurrent platinum-sensitive epithelial ovarian cancer (SOCceR trial): a multicenter randomised controlled study
por: van de Laar, Rafli, et al.
Publicado: (2014)

Sentinel lymph node identification in early stage ovarian cancer: is it still possible after prior tumor resection?
por: Laven, Pim, et al.
Publicado: (2021)

Functional OCT4-specific CD4(+) and CD8(+) T cells in healthy controls and ovarian cancer patients
por: Di, Jiabo, et al.
Publicado: (2013)

External validation of three prognostic models for overall survival in patients with advanced-stage epithelial ovarian cancer
por: van de Laar, R, et al.
Publicado: (2014)

Sentinel node in ovarian cancer: study protocol for a phase 1 study
por: Kleppe, Marjolein, et al.
Publicado: (2013)

Understanding Lymphatic Drainage Pathways of the Ovaries to Predict Sites for Sentinel Nodes in Ovarian Cancer
por: Kleppe, Marjolein, et al.
Publicado: (2015)

Improved preoperative risk stratification with CA-125 in low-grade endometrial cancer: a multicenter prospective cohort study
por: Reijnen, Casper, et al.
Publicado: (2019)

Psoas muscle area is not representative of total skeletal muscle area in the assessment of sarcopenia in ovarian cancer
por: Rutten, Iris J.G., et al.
Publicado: (2017)

Loss of skeletal muscle during neoadjuvant chemotherapy is related to decreased survival in ovarian cancer patients
por: Rutten, Iris J.G., et al.
Publicado: (2016)

Sarcopenia and ovarian cancer survival: a systematic review and meta‐analysis
por: Ubachs, Jorne, et al.
Publicado: (2019)

Investigating the performance and cost-effectiveness of the simple ultrasound-based rules compared to the risk of malignancy index in the diagnosis of ovarian cancer (SUBSONiC-study): protocol of a prospective multicenter cohort study in the Netherlands
por: Meys, Evelyne MJ, et al.
Publicado: (2015)

HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm
por: Van Gorp, T, et al.
Publicado: (2011)

Survival of Ovarian Cancer Patients Is Independent of the Presence of DC and T Cell Subsets in Ascites
por: Wefers, Christina, et al.
Publicado: (2019)

Preoperative HE4 and ROMA values do not improve the CA125 diagnostic value for borderline tumors of the ovary (BOT) – a study of the TOC Consortium
por: Braicu, Elena Ioana, et al.
Publicado: (2014)

Ovarian cancer ascites induces skeletal muscle wasting in vitro and reflects sarcopenia in patients
por: Ubachs, Jorne, et al.
Publicado: (2021)

Collaboration Benefits All
por: Hemida, Reda A., et al.
Publicado: (2020)

CA125 in ovarian tumour tissue at second laparotomy.
por: Maughan, T. S., et al.
Publicado: (1989)

HE4, CA-125, and cystic ovarian mass
por: Wiwanitkit, Viroj
Publicado: (2012)

CA125 and Ovarian Cancer: A Comprehensive Review
por: Charkhchi, Parsa, et al.
Publicado: (2020)

Immunohistochemical expression of MMP-14 and MMP-2, and MMP-2 activity during human ovarian follicular development
por: Vos, Maria Caroline, et al.
Publicado: (2014)

Different Lipid Regulation in Ovarian Cancer: Inhibition of the Immune System
por: Wefers, Christina, et al.
Publicado: (2018)

The added value of SLN mapping with indocyanine green in low- and intermediate-risk endometrial cancer management: a systematic review and meta-analysis
por: Burg, Lara C., et al.
Publicado: (2022)

Laparoscopy to predict the result of primary cytoreductive surgery in advanced ovarian cancer patients (LapOvCa-trial): a multicentre randomized controlled study
por: Rutten, Marianne J, et al.
Publicado: (2012)

Deciphering the Molecular Nature of Ovarian Cancer Biomarker CA125
por: Weiland, Florian, et al.
Publicado: (2012)

CA19-9 as a marker for ovarian cancer: alone and in comparison with CA125.
por: Canney, P. A., et al.
Publicado: (1985)

The Value of CA 125 and CA72-4 in Management of Patients with Epithelial Ovarian Cancer
por: Fayed, Salah T., et al.
Publicado: (1998)

Tumour-associated trypsin inhibitor (TATI) and cancer antigen 125 (CA 125) in mucinous ovarian tumours.
por: Mogensen, O., et al.
Publicado: (1990)

Limited independent prognostic value of MMP-14 and MMP-2 expression in ovarian cancer
por: Vos, M. Caroline, et al.
Publicado: (2016)

Trial of isotretinoin and calcitriol monitored by CA 125 in patients with ovarian cancer.
por: Rustin, G. J., et al.
Publicado: (1996)

Combination of CA125 and RECAF biomarkers for early detection of ovarian cancer
por: Tcherkassova, Janneta, et al.
Publicado: (2011)

TB Peritonitis Mistaken for Ovarian Carcinomatosis Based on an Elevated CA-125
por: Boss, Joseph D., et al.
Publicado: (2012)

Is CA125 useful in monitoring patients with platinum-resistant ovarian cancer?
por: Rustin, G. J. S., et al.
Publicado: (2016)

Exosomal CA125 as A Promising Biomarker for Ovarian Cancer Diagnosis
por: Chen, Zhixiang, et al.
Publicado: (2020)

Combined Preoperative LMR and CA125 for Prognostic Assessment of Ovarian Cancer
por: Tang, Ying, et al.
Publicado: (2020)

VCAM-1 complements CA-125 in detecting recurrent ovarian cancer
por: Song, Jin, et al.
Publicado: (2023)

Ligand-based adoptive T cell targeting CA125 in ovarian cancer
por: Zhao, Haihong, et al.
Publicado: (2023)

Serum CA19‐9, CA‐125 and CEA as tumor markers for mucinous ovarian tumors
por: Lertkhachonsuk, Arb‐aroon, et al.
Publicado: (2020)

The prognostic value of pretreatment CA-125 levels and CA-125 normalization in ovarian clear cell carcinoma: a two-academic-institute study
por: Bai, Huimin, et al.
Publicado: (2016)

CA125-Tn ELISA assay improves specificity of pre-operative diagnosis of ovarian cancer among patients with elevated serum CA125 levels
por: Wang, Yi-Sheng, et al.
Publicado: (2021)

The added value of CA125, HE4, and CA72-4 as markers for ovarian endometriosis diagnosis
por: Micu, Romeo, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jmntsovtk4k8ufd9qjomgvea7h